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IFNγWasting is a sign of various underlying disorders and is a common feature of cancer, sepsis, and AIDS. We
have developed an in vivo model to study the various stages of wasting following infection of mice with lym-
phocytic choriomeningitis virus cl-13. Using this model we have identiﬁed four distinct stages of wasting and
have discovered that all stages occur in the different groups of mice regardless of whether the virus is cleared
or persists. However, the degree and extent of wasting vary between groups of mice, depending upon the
dose of virus administered. Blocking IFNγ or TNFα, which are believed to take part in the wasting process,
did not affect the wasting state. Finally, we found that CD4+ T cells control the maintenance stage of wasting.
We believe this model will be useful in studying the regulation of wasting during a persistent viral infection,
hopefully leading to improved therapies to ameliorate the disorder.
© 2012 Elsevier Inc. All rights reserved.Introduction
Individuals infected with viruses experience a loss in their quality
of life. This loss may be short and transient, such as following an inﬂu-
enza virus infection, or may be life-long, as occurs with a persistent
HIV or hepatitis infection. The host response to a virus infection is
generally responsible for morbidity and mortality. Host responses to
an infection that impact the quality of life include fever, malaise,
and weight loss. Therefore, understanding how the host response to
infection is controlled may provide needed targets to biologically re-
verse the wasting process, increase the quality of life, and decrease
deaths related to wasting in persons infected with acute or chronic
viral infections world-wide.
Wasting is a syndrome associated with many diseases (Delano
and Moldawer, 2006; Doehner and Anker, 2002; Inagaki et al., 1974;
Tisdale, 2002) such as cancer, congestive heart failure, chronic ob-
structive pulmonary disease, HIV, and tuberculosis (TB). The compo-
nents of wasting include weight loss, anorexia, depletion of both fat
and protein masses, muscle atrophy, gain in the proportion of body
water, and a variety of metabolic changes (Langstein and Norton,u (M. Premenko-Lanier).
rights reserved.1991; Norton et al., 1987). Indirect evidence for the role of cytokines
has been derived from studies in which chronic administration of cy-
tokines mimics wasting (Fong et al., 1989; Tracey et al., 1988). More
speciﬁcally, evidence that TNFα has a role in wasting come from ex-
periments in which the wasting syndrome associated with infections
or with tumors is attenuated by treatment with antibodies to neutral-
ize TNFα (Costelli et al., 1993; Gelin et al., 1991; Langstein et al.,
1991; Sherry et al., 1989; Truyens et al., 1995; Yoneda et al., 1991).
However, in many of these studies the administration of anti-TNFα
antibodies not only reduces wasting, but also either reduced tumor
size or parasitemia. Therefore, it is difﬁcult to determine what the
biological effect of anti-TNFα treatment is in these studies.
Additional cytokines have been implicated in wasting. IL-1 has
been shown to induce wasting in rats, similar to TNFα and LPS
(Fong et al., 1989). While IL-6 has been shown to suppress the devel-
opment of wasting associated with tumor growth (Strassmann et al.,
1992). TNFα, IL-1, and IL-6 are triggers of the acute phase response
that is implicated in many diseases (Hirano, 1994). It is the prevailing
hypothesis that wasting develops as a result of chronic overstimula-
tion induced by several cytokines acting in concert and affecting
many different cells and organ systems. However, antagonism of
one or all of these cytokines has not proven clinically beneﬁcial in re-
versing the wasting state (Delano and Moldawer, 2006). Therefore,
investigations into the mechanisms responsible for the development
of wasting are needed.
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(reviews; (Asano and Ahmed, 1995; Oldstone, 2002, 2006; Oldstone
et al., 1985; Yi et al., 2010)). The LCMV model has led to the develop-
ment of experimental therapies to treat persistent infections
(Finnefrock et al., 2009; Larrubia et al., 2009) and towards under-
standing of the differences between acute and persistent viral infec-
tions (Wherry et al., 2003). LCMV has been used to study virus
induced wasting (Doherty et al., 1993; Kamperschroer and Quinn,
2002; Zajac et al., 1996; Zhou et al., 2009). From these LCMV wasting
studies it was found that TNFα does not play a role (Kamperschroer
and Quinn, 2002) in the virus induced wasting, and that CD4+ T
cells were important in the wasting process when CD8+ T cells
were not present or the virus was injected intracranial (Doherty et
al., 1993; Fung-Leung et al., 1991; Zajac et al., 1996; Zhou et al.,
2009). Though CD4+ T cells have been shown to be important in
LCMV induced wasting, their role in the process is poorly understood.
Much of our knowledge about themechanism of wasting is indirect,
detecting serum levels of cytokines or forcing cachexia by continuous
administration of a variety of cytokines or stimulants such as LPS. There-
fore, in vivo models of wasting in natural infections are needed. We
have used the LCMV model as a tool to study the infection-induced
wasting state in vivo. This model has the potential to be valuable in dis-
secting the mechanism of this clinically important, debilitating process.
We have found thatwasting occurs in four distinct phases: 1) initiation,
2) decline, 3) recovery, and 4)maintenance. Our data suggest that each
stage is independently regulated and that speciﬁc therapies to target
each stage may be possible. Speciﬁcally, our data expand on the role
that CD4+ T cells play during the wasting syndrome.
Results
An intermediate dose of cl-13 leads to enhanced morbidity
We investigated the effect of 5-fold differences in the infectious dose
on morbidity after cl-13 infection. Wemade ﬁve-fold dilutions of cl-13,
using a very high (1×107 pfu), high (2×106 pfu), intermediate (4×105Fig. 1. An intermediate dose of LCMV cl-13 leads to enhanced morbidity. Mice were infected
(green ✖), or very high (1×107 pfu) (orange □) dose of LCMV cl-13 intravenously, or unin
independent experiments. Error bars=mean error+SD. p=0.0001 2-way ANOVA virus do
the intermediate dose infection to all other groups of mice. b. Illness scores of mice infecte
with the different doses of cl-13. d. Day 60 post-infection viral titers in the kidney. Dashed
experiments.pfu), and low (8×104 pfu) dose of virus to infect C57BL/6mice intrave-
nously. Mice infected with different doses of cl-13 had strikingly differ-
ent patterns of morbidity (Fig. 1a). All animals lost a small amount of
body weight during the ﬁrst 2 days of infection, and then recovered.
They then underwent a second round of body weight loss beginning
6 days post infection. Differences in morbidity between the groups
were observed by 8 days post-infection. In this second wave of weight
loss, mice infected with a low dose of cl-13 lost signiﬁcantly less body
weight than all other groups of mice, and regained this body weight
by day 10 post infection (Fig. 1a, p=0.001 two-way ANOVA). Mice
infected with high (2×106) or very high (1×107) doses of virus expe-
rienced wasting typical of cl-13 infected mice, losing about 20% of
their bodyweight by day 8 post-infection. To our surprise,mice infected
with the intermediate dose of cl-13 experienced enhanced wasting and
prolonged morbidity relative to the higher and lower virally infected
groups (Fig. 1a, open circles).
Differences in the clinical outcome were also apparent in illness
scores. Animals infected with the intermediate dose of virus showed
high illness scores until about 16 days post-infection as compared to
animals given the higher doses (Fig. 1b). Intriguingly, animals given
the low dose of cl-13 did not experience apparent illness beyond
their moderate weight loss (Fig. 1b), though the initial infectious
dose was only ﬁve-fold lower than the dose causing the greatest ill-
ness. Mice infected with the rapidly cleared LCMV Armstrong strain
at 2×106 pfu i.v., had a similar disease course as compared to the
low dose LCMV cl-13 infection (data not shown).
Having observed this dose-dependent pattern of morbidity and ill-
ness in LCMV cl-13 infected mice we investigated whether variation
in disease was due simply to corresponding changes in viral load.
Mice were bled weekly and titers in the plasma were determined by
plaque assay. At 1 week post-infection almost all mice infected with
the low dose of virus had undetectable plasma viremia (Fig. 1c), sim-
ilar to what is seen using the less pathogenic Armstrong strain of
LCMV, (Wherry et al., 2003) and from our own experiments with
Armstrong (data not shown). Mice infected with intermediate, high
and very high doses of virus had similar titers of LCMV in their plasmawith a low (8×104 pfu) (red ■), intermediate (4×105 pfu) (blue○), high (2×106 pfu)
fected (black line). a. Percent body weight loss following infection, pooled data from 5
se and % body weight loss were compared between 8-15 days post infection between
d with the different doses of cl-13. c. Plasma viral loads of individual animals infected
line indicates limit of detection. Results are representative of at least 3 independent
124 A. Stamm et al. / Virology 425 (2012) 122–132at weeks 1, 2 and 3 post-infection (Fig. 1c). Mice infected with low
dose cl-13 were able to control virus in all infected tissues between
15 and 22 days post infection (data not shown) whereas mice
infected will all other doses of the same virus inoculum had virus ti-
ters measurable in the kidney (Fig. 1d) and brain (data not shown)
out to day 60 post infection. Thus, differences in viral titers by the
ﬁrst week of infection did not explain the differences in wasting ob-
served in the medium, normal, and high dose groups at this time.
Viral titers are controlled very early in low dose-infected mice but do not
fully explain differences in morbidity
We reasoned that events occurring early following infection may
determine the morbidity differences that emerged at day 8 post-
infection. Therefore, we closely examined the relationship between
virus dose and very early kinetics of tissue viral loads. By day 5 post
infection, there were no signiﬁcant differences in viral titers mea-
sured between all groups of cl-13 infected mice (data not shown).
By day 6 in the liver, the low dose infected mice had signiﬁcantly
lower levels of virus that continued through day 8 of the infection
(Fig. 2). This pattern was also true in the brain but not the kidney
(Fig. 2). On day 8 post infection, the low dose group viral titers in
the kidney were not signiﬁcantly different than the other infectedFig. 2. Virus replication is controlled early in the brain of mice infected with low dose cl-13
(2×106 pfu, ×) dose of LCMV cl-13 intravenously, or uninfected. LCMV titers in tissues wer
post-infection in the liver (a), kidney (b) and brain (c) titers. All statistics were done using
experiment, error bars represent mean.groups of mice. Mice infected with the intermediate and high doses
of virus had increasing levels of virus in the brain on days 7 and
8 post infection, while low dose mice rapidly established control of
viral replication in the brain.
Overall, mice infected with the low dose of cl-13 had signiﬁcantly
reduced viral titers in all tissues tested, indicating that a systemic in-
fection was transiently established and then rapidly cleared. Also of
interest, the intermediate dose groups' viral titers in tissues were sim-
ilar to or lower than the high dose group at these early time points. By
day 15, cl-13 was cleared from the low dose infected mice and there
was no signiﬁcant difference between the intermediate and high dose
infected animals (data not shown). Thus, the prolonged morbidity
and illness observed in the intermediate dose group as compared to
the high dose group cannot be explained by greater amounts of
virus replicating in their tissues.
Differences type I IFN production and CD69 expression on CD4+ and
CD8+ T cells
We next hypothesized that immunological events within the ﬁrst
week of infection determined the course of disease. Since clearance of
LCMV requires CD8+ T cells (Moskophidis et al., 1987), we examined
T cell responses over time in the blood. All groups experienced a.Mice were infected with a low (8×104 pfu, ■), intermediate (4×105 pfu, ○), or high
e measured on Day 6 (ﬁrst column), Day 7 (second column) and Day 8 (third column)
the student's t-test. Data pooled from 2 independent experiment n=3–5 mice/group/
125A. Stamm et al. / Virology 425 (2012) 122–132similar drop in total CD8+ T cells in the blood during the ﬁrst 3 days
after infection (data not shown). Other groups have attributed this
early attrition of T cells to type I interferon (IFN-I) (Bahl et al.,
2006). Mice infected with the low dose cl-13 had a signiﬁcantly
lower IFN-I response in the plasma compared to those infected with
higher doses of cl-13 (Fig. 3a, one way ANOVA p=0.006). Type I
IFN levels waned over time and are undetectable in all groups on
days 5–8 post-infection (data not shown). The signiﬁcantly reduced
levels of type I IFN in the low dose infected group of mice correlated
with their reduced levels of CD69 expression on both CD4+ and
CD8+ T cells (Figs. 3b–d). CD69 is upregulated non-speciﬁcally on T
cells following an LCMV infection, probably in response to IFN-I
(Shiow et al., 2006).
Mice infected with low dose cl-13 have more peripheral total CD8+ and
CD4+ T cells and altered patterns of PD-1 expression
By day 8 post-infection, the low dose group had signiﬁcantly elevat-
ed numbers of CD8+cells (Fig. 4a, p=0.0001 oneway ANOVA), LCMV-
speciﬁc GP33-tetramer positive cells (Fig. 4b, p=0.0001, one-way
ANOVA) and CD4+ T cells in the blood (Fig. 4c, p=0.0001, one-way
ANOVA). CD8+ T cell counts in the other groups of LCMV-infectedFig. 3. Differences type I IFN production and CD69 expression on CD4+ and CD8+ T cells.M
uninfected. a. Day 1 post infection type I IFN was measured using a bioassay. b. CD69 GM
infection. d. A representative histogram of CD69 expression on CD4+ and CD8+ T cells 1 da
* pb0.01, ** pb0.001 by student's t test.mice rebounded to normal levels by day 8, but were not signiﬁcantly
different from each other. Therefore, mice infected with 8×104 pfu of
cl-13 had increases in both CD4+ T cells and CD8+ T cells while all
other groups showed equivalent (or lower) CD4+ T cell and CD8+ T
cell counts in the blood. This increase in absolute counts in low-dose
infected mice appeared to be due to expansion of LCMV-speciﬁc cells.
Following activation, antigen speciﬁc T cells upregulated PD-1
(Barber et al., 2006). Interestingly, we noticed that mice infected
with the low dose of cl-13 had differences in PD-1 expression on
CD8+ and CD4+ T cells. PD-1 was expressed on the CD4+ T cell ef-
fector population (CD44+CD62LLo) in mice infected with the low
dose of virus at 1 and 2 weeks post infection and then signiﬁcantly
down regulated by 3 weeks post infection (Fig. 4d and e, p=0.0001
one way ANOVA). On CD8+ T cells we observed a different pattern
of PD-1 expression: by day 8 post-infection, CD8+ T cells from mice
given the low dose of cl-13 had signiﬁcantly lower levels of PD-1 ex-
pression than CD8+ T cells from mice infected with the higher doses
of virus (Figs. 4f and g, p=0.001 one way ANOVA). The difference in
PD-1 MFI appeared to be due to lower levels of PD-1 expressed on
LCMV-speciﬁc CD8+ T cells, as revealed by staining with a GP33-
speciﬁc tetramer (Figs. 4h and i, p=0.0001 one way ANOVA). Virus
is still present in the organs of the low dose-infected mice at thisice were infected with 8×104 pfu, 4×105 pfu, 2×106 pfu or 1×107 pfu clone 13 i.v., or
FI on CD4+ T cells, Day 1 post-infection. c. CD69 GMFI on CD8+ T cells, Day 1 post-
y post LCMV cl-13 infection. Data are representative of 2–3 independent experiments.
Fig. 4. Differences in total peripheral T cells and PD-1expression on CD4+ and CD8+ T cells.Mice were infected with 8×104 pfu, 4×105 pfu, 2×106 pfu or 1×107 pfu clone 13 i.v., or
uninfected control. a–c. Day 8 post infection total cells/ml blood. a. Total CD8+ T cells. b. LCMV gp33 tetramer+CD8+. c. Total CD4+ T cells. d, f, h. Day 8 (white bar), Day 15
(black bar) and Day 22 (gray bar) post infection PD-1 GMFI on d. CD44+ CD62L-CD4+ effector CD4+ T cells. e. Representative contour plots of effector CD4+ T cells. f. CD44+
CD62L-CD8+ effector CD8+ T cells g. representative contour plots of effector CD8+ T cells and h. LCMV speciﬁc gp33 CD8+ T cells, plot gated on CD8+ effector T cells and i. rep-
resentative contour plots of gp33 T cells gated on effector CD8+ T cells. Data are representative of 2–3 independent experiments. * pb0.01, ** pb0.001 ANOVA or student's t test.
126 A. Stamm et al. / Virology 425 (2012) 122–132time (Fig. 2), so these data indicate that PD-1 down regulation on
CD8+ T cells does not strictly correlate with clearance of the viral
antigen (Sharpe et al., 2007).
With respect to the high and very high dose groups (2×106 and
1×107 pfu), PD-1 expression was not signiﬁcantly altered between
weeks 1–3 post infection. We did detect a signiﬁcant difference in
the level of PD-1 expression on CD4+ T cells that were CD44high
CD62LLo (effector cells) in the intermediate (4×105 pfu) dose group
1-week post infection (Figs. 4d and e). In addition, we found that
mice infected with the intermediate dose of virus had a signiﬁcant in-
crease in the level of PD-1 expression on both CD8+ T effector cells
and GP33-speciﬁc CD8+ T cells at week 2 post infection (Figs. 4f
and g, p=0.0004 and 0.0003 respectively, one way ANOVA). These
data show that an increased frequency of activated, PD-1 expressing
T cells was correlated with prolonged morbidity when present in con-
junction with high levels of virus (Fig. 1a).An early CD4+ T cell response is followed by a signiﬁcant expansion of
the CD8+ T compartment in mice infected with the low dose of cl-13
Since differences between the peripheral T cell responses in the var-
ious groups of mice were evident by day 8 post-infection (Figs. 4d–i),
we decided to focus on early antigen-speciﬁc T cell responses. Mice
were infectedwith low, intermediate, and high doses of cl-13 and sacri-
ﬁced on days 6, 7, and 8 post-infection. These time points correspond
divergence of different groups of mice in the extent of their weight
loss. Functionality of antigen-speciﬁc splenic T cells was examined. At
day 6 post-infection, both CD4+ and CD8+ T cell responses to immu-
nodominant epitopes were readily detectable (Figs. 5a, c–d). On day 6
post-infection, mice infected with the low dosemade signiﬁcantly larg-
er CD4+ T cell responses to the GP61 epitope than those made bymice
that received the intermediate and high doses of virus (Figs. 5a and b,
p=0.01 one-way ANOVA). The difference in magnitude of CD4+ T
Fig. 5. An early CD4+ T cell response is followed by a signiﬁcant expansion of the CD8+ T compartment in mice infected with the low dose of cl-13.Mice were infected with a low
(8×104 pfu), medium (4×105 pfu), high (2×106 pfu), or very high (1×107 pfu) dose of LCMV cl-13, or were uninfected (control). On days 6–8 post infection, some mice in each
group were sacriﬁced and intracellular cytokine production by splenocytes was measured following in vitro LCMV peptide stimulation. a. gp61 stimulated splenocytes, gated on
CD4+ T cells. Number indicates the percentage of CD4+ cells that were IFNγ positive. b. Total numbers of IFNγ producing cells were quantiﬁed in mice infected with uninfected
control (gray bar), 8×104 pfu (black bar), 4×105 pfu (striped bar), or 2×106 pfu (white bar) following stimulation of CD4+ T cells with gp61. c. gp33 stimulated splenocytes, gated
on CD8+ T cells. Number indicates the percentage of CD8+ cells that were IFNγ positive. d. np396 stimulated splenocytes, gated on CD8+ T cells. e–f. Total numbers of IFNγ pro-
ducing cells were quantiﬁed in mice infected with uninfected control gray bar, 8×104 pfu (black bar), 4×105 pfu (striped bar), or 2×106 pfu (white bar) following stimulation;
stimulation of CD8+ T cells with (f) gp33 or (g) np396. x axis indicates day post infection, error bars represent mean+SD. * pb0.01, ** pb0.001 student's t test. Results are rep-
resentative of two independent experiments, n=4–5/group.
127A. Stamm et al. / Virology 425 (2012) 122–132cell responses between low dose mice and the intermediate or high
dose mice continued through day 8 post infection (Fig. 5a). At that
time the low dose-infected mice had GP61-speciﬁc responses, which
were 3 to 5-fold larger in frequency than responses made by mice
that received higher doses of virus (Fig. 5b, day 7 p=0.0043 and day
8 p=0.04, one-way ANOVA).
In the CD8+T cell compartment, all groups of micemade responses
against GP33 and NP396 of comparable frequency at day 6 post-
infection, as measured by IFNγ/TNFα secretion in response to peptide
(Figs. 5c and d). However, the np396 response was signiﬁcantly elevat-
ed in mice infected with low dose cl-13 as compared to mice infected
with the very high dose. By days 7 and 8 post-infection though, the dif-
ference in themagnitude of the CD8+T cell responsesmade by the low
dose group and the other groups was dramatic (Figs. 5e and f, day 7
gp33 p=0.0001, np396 p=0.001 and day 8 gp33 p=0.03 and np396
p=0.01, one-way ANOVA). The low dose cl-13 infected mice made 2
to 10 fold higher frequency responses compared to intermediate and
high dose groups. The magnitude of responses made by the intermedi-
ate and high dose groups was similar to each other.
In summary, mice infected with a low dose of cl-13 (8×104 pfu)
had a higher frequency of CD4+ T cells 6 days post-infection as com-
pared to mice infected with the intermediate or high doses. This di-
vergence in CD4+ T cell response magnitude was followed by a
divergence in the magnitude of CD8+ T cell responses on days 7
and 8 post infection (Figs. 5b, e and f). These results indicate that
the expansion phase of T cell responses against LCMV was affected
by the initial dose of virus given, with a lower initial dose resulting
in signiﬁcantly larger T cell responses. This robust response occurred
at the same time viremia was being cleared in these animals and
these mice experienced the least severe wasting (Fig. 1a).Measurement of pyrogens in plasma
The rapid clearance of virus observed in mice infected with the low
dose of cl-13was associatedwith reducedmorbidity (Fig. 1a). However,
neither quantitation of early T cell responses nor of viral loads satisfac-
torily explained the enhanced morbidity experienced by the mice
infected with an intermediate dose (4×105 pfu) as compared to mice
that received higher doses of cl-13. This led us to quantitate the levels
of plasma cytokines that have been previously implicated in immuno-
pathology (Kamperschroer and Quinn, 2002) and referred to as pyro-
gens. Pyrogens are substances that induce a fever response. Well-
characterized pyrogens include TNFα and IL-1β (Stefferl et al., 1996).
We performed a Luminex assay to determine whether we could detect
differences in cytokine levels known to be important in morbidity and
wasting. From each dose group, we randomly tested six mice from
two independent experiments for cytokinemeasurement and observed
no differences in IL-6, IL-10, or IL-1β levels between the groups (data
not shown). Therewas a peak of IFNγ production at day 6 post infection
thatwas reduced at least ﬁve-fold by day 7 post infection in all groups of
infected mice (Fig. 6a). Interestingly, mice infectedwith 2×106 pfu had
a signiﬁcant reduction in circulating levels of IFNγ at day 6 as compared
to the low dose infected mice (Fig. 6a). We also detected increased
levels of TNFα 6 days post infection in all infected groups (Fig. 6b). In
the low dose-infected group, this TNFα peak was reduced by day 7
andwas undetectable by day 8. In contrast, TNFα levelswere detectable
in the plasma of mice infected with the normal or medium doses of cl-
13 out to 15 days post infection (Fig. 6b).
These data suggested that IFNγ and TNFα levels might have a role
in the increased morbidity experienced by the mice infected with an
intermediate dose of cl-13. We reasoned that blocking TNFα or IFNγ
Fig. 6. Levels of cytokines do not explain enhanced morbidity.a. IFNγ plasma levels as determined by a Luminex assay performed on samples taken from mice infected with 8×104
(■), 4×105 (○) or 2×106 pfu (×). (8×104 pfu p=0.0301 as compared to 2×106 pfu, student's t-test) b. TNFα plasma levels, as determined by Luminex assay. Mice infected with
4×105 pfu had a signiﬁcant increase in TNFα (p=0.0498) on day 6 as compared to 2×106, (n=6/group). c–e. Mice were infected with 4×105 pfu of virus and treated on days 5
and 7 with either 200 μg/treatment of anti-IFNγ or 100 μg/treatment of anti-TNFα antibodies. c. Percentage body weight loss following treatment, gray is uninfected, untreated
4×105 pfu (■), anti-IFNγ (○) and anti-TNFα (×), error bars represent mean+SD. d. Kidney viral titers, day 15 post-infection. e. Brain viral titers, day 15 post-infection. Data
are representative of two independent experiments, n=4–5/group.
128 A. Stamm et al. / Virology 425 (2012) 122–132might thus ameliorate the prolonged morbidity. To test this hypothe-
sis, mice were infected with 4×105 pfu of cl-13 and treated on days 5
and 7 with either IFNγ or TNFα neutralizing antibodies. Treatment
had no effect on morbidity (Fig. 6c) or viral titers (Figs. 6d and e).
Our results conﬁrm previous studies using anti-TNFα antibodies dur-
ing an LCMV infection (Kamperschroer and Quinn, 2002). Our lab has
also used the IFNγ blocking antibody to successfully reverse the anti-
viral state following an in vivo cl-13 infection (unpublished data).
Therefore, we believe that both blocking antibodies were used at a
biologically relevant dose. Although levels of IFNγ and TNFα were el-
evated following infection with the different doses of cl-13, blocking
these pyrogens individually was not sufﬁcient to ameliorate morbid-
ity. Therefore, IFNγ and TNFα have a role in inﬂammation, they do
not individually inﬂuence wasting in our model.
CD4+ T cells maintain the wasting disease following the intermediate
dose of cl-13
CD4+ T cells are known to play a role in morbidity following an
LCMV infection (Doherty et al., 1993; Fung-Leung et al., 1991; Zajac
et al., 1996; Zhou et al., 2009). Therefore we wanted to investigate
if CD4+ T cells were impacting wasting in our model. Since the wast-
ing state initiates between days 5–6 in all groups, we tested whetherdepleting CD4+ T cells on day 5 following infection with the different
doses of cl-13 would perturb morbidity. Depleting CD4+ T cells was
effective following GK1.5 antibody administration 5 days post cl-13
infection (data not shown). Following depletion, CD4+ T cells reap-
pear in the circulation within 1 week (data not shown). CD4+ T cell
depletion did not affect the initiation of wasting state following cl-
13 infection (Figs. 7a-c). However, 5 days after depletion of CD4+ T
cells the mice began to recover more rapidly than untreated infected
controls (Figs. 7a–c). By 11 days post infection mice depleted of
CD4+ T cells have a signiﬁcant increase in the body weight
(Fig. 7d). The recovery of body weight was independent of virus
loads because treated mice had the same levels of virus as untreated
mice (Figs. 7e and f). Clearance of the virus in the low dose infected
group was not altered in CD4 depleted animals (data not shown). In
addition CD8+ T cell responses were not altered when CD4+ T
cells were depleted at this time (Fig. 7g). These data suggest that
the presence of CD4+ T cells is not required to initiate wasting, but
CD4+ T cells are required to maintain the morbid state.
Discussion
Wasting is a debilitating, difﬁcult to treat condition that is an es-
sential part of the pathology of many diseases. Here we describe an
Fig. 7. CD4+ T cells are required to maintain the wasting disease following a cl-13 infection. WT mice were infected with the low, intermediate or high LCMV clone 13. On day 5 post infection some mice were depleted of CD4+ T cells using
the GK1.5 antibody (indicated by arrow). a–c. Percent loss of body weight of intact (solid line) or CD4-depleted (dashed line) animals infected with a. low, b. intermediate or c. high dose of cl-13. d. Day 11 post infection % body weight loss.
All statistics were done using the student's t-test. e–f. LCMV titers in tissues were measured 3 weeks after infection with e. Intermediate and f. high dose of LCMV cl-13. d. Representative plot of splenocytes that were stimulated with LCMV
gp33 peptide and IFNγ production was measured. Number indicates % of CD8+ Thy1.2+ cells making IFNγ. All error bars indicate mean+SD. Data from two independent experiments are displayed.
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Fig. 8. Proposed stages of morbidity following LCMV cl-13 infection. Mice infected with
a low dose (8×104 pfu solid gray line), a medium dose (4×105 pfu dashed black line)
or a high dose (2×106 pfu dotted gray line) of cl-13. % original body weight was mon-
itored for 30 days post-infection. Stages: 1) initiation, 2) decline, 3) recovery, and 4)
maintenance.
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(Fig. 1). In our model, infection with different doses of the same virus
leads to marked differences in the severity of morbidity. These differ-
ences were not explained completely by either differences in the
levels of viremia or by the immune responses engendered, but
appeared to be a result of the interaction of these two variables. We
have found and conﬁrmed that TNFα (Kamperschroer and Quinn,
2002) is not sufﬁcient to drive wasting, despite its presence during
cachexia.
The initial interactions of the pathogen and the host are critical.
Our model demonstrates that the initial virus dose has an important
role in determining the outcome of disease. We describe a system in
which a potentially persistent viral infection is either cleared by the
host without causing discernable illness, or establishes a persistent in-
fection characterized by signiﬁcant wasting and immune exhaustion.
Diseases such as hepatitis C (HCV) (Lewis-Ximenez et al., 2010), and
hepatitis B (HBV) (Webster and Bertoletti, 2002) have similar diverse
outcomes in humans. Once an infection has been established, it is
difﬁcult to determine whether immunological responses correlated
with particular outcomes are causes or consequences of the persistent
infection. Ourmodel supports wasting as a common biological process
regardless of whether the virus is cleared or persists.
Following administration of the lowest dose of cl-13, 8×104 pfu a
systemic infection is established and then rapidly cleared by robust T
cell responses with little apparent illness. However, administration of
only ﬁve-fold more viruses to mice results in sustained morbidity and
the establishment of a persistent infection. Differences in virus load
(Figs. 1 and 2) do not explain the differences in disease outcome be-
tween the intermediate and high dose infected groups. During the pe-
riod of wasting, the virus load between the intermediate and high
dose groups of mice is not signiﬁcantly different although mice
infected with the high dose of cl-13 recover more rapidly than mice
infected with the intermediate dose of virus (Fig. 1a).
It has been well established that T cells contribute to the patholo-
gy of LCMV infection. Therefore, we investigated whether differences
in T cell responses could account for differences in wasting. PD-1
levels on CD4+ T cells 8 days following infection and PD-1 levels on
CD8+ T cells 15 days post infection are signiﬁcantly increased in
mice infected with the intermediate dose of cl-13 as compared to all
other groups of infected mice, (Figs. 4d and f respectively) indicating
greater T cell activation. Two weeks following infection, a time when
PD-1 levels remain elevated in the intermediate dose group, the mice
begin to recover from wasting. When CD4+ T cell PD-1 levels are sig-
niﬁcantly increased in the intermediate dose group 8 days post infec-
tion, mice are maintaining their morbid state. Therefore, altered
CD4+ T cell activation 1 week post infection in the intermediate
dose group may drive the enhanced wasting.
CD4+ T cells have also been implicated in wasting, but their exact
role is unknown (Doherty et al., 1993; Fung-Leung et al., 1991; Zajac
et al., 1996; Zhou et al., 2009). Some of these published studies sug-
gest that CD4+ T cells have a role in wasting when CD8+ T cells
are also depleted. These results demonstrate that without both
CD4+ T cells and CD8+ T cells wasting does not occur. Using our
model we found that depletion of CD4+ T cells led to a more rapid re-
covery fromwasting in all mice infected with cl-13 regardless of dose,
(Figs. 7a–d) and independent of virus load (Figs. 7e–f). Although,
mice infected with the intermediate dose of cl-13 and depleted of
their CD4+ T cells had the most signiﬁcant difference in morbidity
(Fig. 7b), these mice do not normally recover from morbidity until
3 weeks following infection (Fig. 1a). The low and high dose infected
mice naturally have a period of recover (Fig. 1a) and CD4+ T cell de-
pletion accelerates this recovery period (Figs. 7a and c). This suggests
that CD4+ T cells contribute to the maintenance of wasting and fur-
ther prevent mice infected with the intermediate dose of virus from
entering a recovery period. It is important to point out that while
there do not appear any obvious differences in the CD4+ T cellresponse following the intermediate and high doses of cl-13, the in-
termediate has a prolonged morbid state that CD4 depletion partially
reverts. Therefore, other to be determined factors may also contribute
in maintaining the morbid state. We are currently investigating
whether the CD4+ T cell response transitions from an early effector
to a regulatory response during the maintenance stage of wasting
(Fahey et al., 2011). Additionally, we have depleted CD8+ T cells in
the low dose infected mice at 5 days following infection. CD8+ T cell
depletion exasperated the morbid state (data not shown) and there-
fore was not attempted in the higher dose groups. Other cells such
as antigen presenting cells may play a role in this complex process.
TNFα, also known as cachectin, is known to cause a lethal state of
shock and a chronic wasting syndrome when produced in abundance
(Araki et al., 2009; Beutler and Cerami, 1988). Pro-inﬂammatory cyto-
kines play a role in LCMV wasting disease when the virus is adminis-
tered by intracranial inoculation (Kamperschroer and Quinn, 2002).
In the present study we found that both IFNγ and TNFα were elevat-
ed during the wasting state (Figs. 6a–b). However, we did not ﬁnd an
obvious relationship between TNFα or IFNγ and the enhanced mor-
bidity and wasting in mice infected with the intermediate cl-13
dose of 4×105 pfu (Figs. 6c–e). Thus it is possible that the presence
of these inﬂammatory cytokines during virus induced wasting may
be correlative but not causative.
Using our model of LCMV cl-13 infection we propose that wasting
occurs in 4 distinct stages: initiation, decline, recovery, and mainte-
nance (Fig. 8). Depending on the dose of the original inoculum, the
time that each group enters a particular stage, or transitions to the
next stage, is different. We did not ﬁnd that increased viral titers nec-
essarily corresponded to increased wasting. Nor did we ﬁnd that mice
that had a very strong T cell response experienced more wasting.
Rather, the interaction of these two parameters may underlie the ill-
ness observed. Using this model, in which the same virus causes dif-
ferent degrees of pathology, we hope to further elucidate how the
different stages of wasting are regulated in the context of a viral infec-
tion. This knowledge may then prove useful in developing interven-
tions to ameliorate the symptoms associated with many diseases.
Materials and methods
Mice and virus
Female wild type C57BL/6 mice were purchased from Charles
River Laboratories (Wilmington, MA) and used at 6-8 weeks of age.
All mice were maintained under speciﬁc pathogen-free conditions
at the UCSF SFGH animal facility and were used in accordance with
university animal welfare guidelines. LCMV cl-13 and Armstrong
were a gift from Dr. Mehrdad Matloubian and were propagated on
BHK cells. Age- and sex-matched animals were given 5-fold dilutions
of cl-13 virus made in serum-free RPMI (8×104, 4×105, 2×106 or
131A. Stamm et al. / Virology 425 (2012) 122–1321×107 pfu) by tail-vein injection. LCMV Armstrong was used at a
dose of 8×104 or 2×106 pfu. Following infection, mice were weighed
daily for the ﬁrst month then weekly thereafter. Body weight was cal-
culated as a fraction of a mouse's starting body weight. Mice were
scored for illness by giving a point for each of the following condi-
tions: rufﬂed fur, weight loss exceeding 15%, visually lethargic, lethar-
gic to the touch, and a hunched back. Mice were euthanized according
to an approved IACUC protocol. Titers of virus were determined by
plaque assay on Vero cells as previously described (Ahmed et al.,
1984).
Type I IFN bioassay
Type I interferon bioassay was used to measure IFN-I as described
(Cembrzynska-Nowak, 1989). The murine IFN standard (Biomedical
Laboratories PBL, 12100-1) at a ﬁnal concentration of 100 U ml−1
was used as a control.
Sample collection, cell suspension and ﬂow cytometry
Heparinized blood was collected by tail vein nick. The blood was
spun down at 12,000 rpm and the plasma collected for plaque and cy-
tokine assays. Blood cells were then resuspended and stained for
15 min at room temperature with ﬂuorochrome-conjugated anti-
bodies. Fluorochrome-conjugated antibodies were obtained from BD
Pharmingen (San Diego, CA), and eBiosciences (San Diego, CA). Red
blood cells were lysed using BD FACS Lysing Solution (BD Biosciences,
Franklin Lakes, NJ); cells were washed twice in FACS Buffer (PBS/
1%BSA), and ﬁxed (PBS/1% PFA) prior to running on a ﬂow cytometer.
Single cell suspensions of splenocytes were prepared by mashing the
spleen through a 70 μm cell were lysed using ACK Buffer (Sigma-
Aldrich, St Louis, MO) and washed with RPMI. For intracellular cyto-
kine staining assays, splenocytes were resuspended in RPMI supple-
mented with 10% FCS (Hyclone) and stimulated with 2.5 μM peptide
for 6 h at 37 °C in the presence of GolgiPlug (BD Biosciences). Cells
were stained for surface and intracellular markers using the BD
Cytoﬁx/Cytoperm Kit following manufacturer's protocol. Tetramers
(GP33) were by synthesized by the Microchemical Facility Core
(Emory University, Atlanta, GA). Samples were read on an LSRII
ﬂow cytometer (BD Biosciences) and results were analyzed using
FlowJo software (TreeStar, Ashland, OR).
Peptides
Peptides gp33-41 (KAVYNFATM), np366-374 (ASNENMDAM), and
gp61-80 (GLNGPDIYKGVYQFKSVEFD), were synthesized by Anaspec
(Fremont, CA).
In vivo antibody treatment
CD4+ T cell depletion was done using the antibody clones GK1.5
at 500 μg/mouse/dose administered at the indicated time points i.p.
Anti-IFNγ antibodies were administered at 200 μg/mouse/dose at in-
dicated time points i.p. Anti-TNFα antibodies were administered at
100 μg/mouse at the indicated time points. GK1.5, and anti-IFNγ anti-
bodies were provided by the UCSF hybridoma core facility. Anti-TNFα
antibodies were purchased from MyBioSource, (MBS670094, Rat
Anti-Mouse TNF-a-LE/AF).
Luminex analysis
For Luminex assays, plasma was thawed at room temperature,
gently vortexed, then centrifuged at 13,200 rpm for 10 min at 4 °C
immediately prior to testing. Cytokines were measured using a MILLI-
PLEX MAP High Sensitivity Mouse Cytokine Panel (7-plex, Millipore)according to the manufacturer's instructions. Plates were read on a
Luminex-100 (Millipore) with Masterplex QT software (MiraiBio).Statistical analysis
Statistical signiﬁcance was determined by Standard two tailed T-
test or 1 or 2-way ANOVA, using Prism 5 (Graphpad Software, La
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